Funding for this research was provided by:
Daewoong Pharmaceutical Company (Daewoong 19-329)
Received: 25 October 2019
Accepted: 28 March 2020
First Online: 22 April 2020
Ethics approval and consent to participate
: The study protocol and other associated documents have been approved by the IRB of Gachon University Gil Medical Center and other local IRBs of participating centers. The principal investigators or sub-principal investigators will be responsible for obtaining written informed consent from patients before enrollment. The informed consent form is available from the corresponding author on request.
: Not applicable.
: All authors declare that they have no competing interests from Dae-woong Pharmaceutical Co. Ltd (Seoul, South Korea) or other partners.